SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant to~~PURSUANT ~~Section~~TO SECTION 13 orOR 15(d) ofOF ~~the Securities Exchange Act of 1934~~

~~Date of~~THE ~~Report~~SECURITIES ~~(Date~~EXCHANGE ofACT ~~earliest~~OF ~~event reported): October 23, 2018 (October 23, 2018)~~1934

~~Commission file~~Date ~~number~~of Report (Date of earliest event reported): ~~333-208934~~January 7, 2026 (November 30, 2025)

~~RELIANT SERVICE~~QUANTUMZYME ~~INC~~CORP. (Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)

Nevada	000-56725	N/A
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

Nevada		36-4806481
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

15656 Bernardo Center Drive Suite 801

~~Room 1202,~~San ~~No. 22-2625 Pingliang Road~~Diego, ~~Yangpu District, Shanghai, China.~~ CA 92127

~~(Address of~~Tel.: ~~principal executive offices)~~858-203-0312

~~86- 13166667122~~(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

~~(Company’s Telephone~~Securities ~~Number,~~registered ~~Including~~pursuant ~~Area~~to ~~Code~~Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered N/A N/A N/A

~~(Former name,~~Check ~~former~~the ~~address~~appropriate ~~and~~box ~~former~~below ~~fiscal~~if ~~year,~~the ifForm ~~changed~~8-K ~~since~~filing ~~last~~is ~~report~~intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~Check~~ ☐ Written communications pursuant to Rule 425 under the ~~appropriate~~Securities ~~box~~Act ~~below~~(17 ifCFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the ~~Form~~Exchange 8Act (17 CFR 240.14a-K12) ~~filing~~☐ isPre-commencement ~~intended~~communications pursuant to ~~simultaneously~~Rule ~~satisfy~~14d-2(b) under the ~~filing~~Exchange ~~obligation~~Act of(17 ~~the~~CFR ~~Company~~240.14d-2(b)) ~~under any~~☐ ofPre-commencement communications pursuant to Rule 13e-4(c) under the ~~following~~Exchange ~~provisions:~~Act (17 CFR 240.13e-4(c))

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ~~[X]~~☒

~~If an~~QUANTUMZYME emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActCORP. ~~[ ]~~

~~Item 1.01.~~Form ~~Entry into a Material Definitive Agreement~~8-K

~~On October~~Current 23, 2018, Reliant Service Inc., a Nevada corporation (hereinafter referred to as “RLLT” or “Company”), Coolpaul Holding Group Co., Ltd., a Cayman Islands limited liability company (“CPRC”), and five stockholders set forth in Schedule A of Exhibit 10.1 to this Form 8-K (as described below), who collectively hold 100% of the issued and outstanding capital stock of CPRC (the “Stockholders”), entered into a share exchange agreement (the “Share Exchange Agreement”). Pursuant to the Share Exchange Agreement, the Company will issue 50,000,000 shares (the “New Shares”) of the Company’s common stock to the Stockholders (or their designees), and transfer these New Shares to the Stockholders (or their designees), which collectively shall represent 66.67% of the issued and outstanding common stock of the Company immediately after the closing, in exchange for 50,000,000 ordinary shares of CPRC (the “CPRC Shares”), representing 100% of the issued share capital of CPRC. As a result of the exchange of the CPRC Shares for the New Shares (the “Share Exchange”), CPRC will become a wholly owned subsidiary of the Company and there will be a change of control of the Company following the closing.Report

~~The Share~~Item ~~Exchange will be subject to customary closing conditions~~5.03 A– ~~copy~~Amendments ~~of the Agreement dated October 23, 2018 is filed as Exhibit 10.1~~ to ~~this~~Articles ~~Form 8-K. The foregoing description~~ of ~~the~~Incorporation ~~Share~~or ~~Exchange~~Bylaws; ~~does~~Change ~~not purport to be complete and is qualified~~ in ~~its entirety~~Fiscal ~~by reference to the complete text of the Agreement, which is filed as Exhibit 10~~Year.~~1 hereto, and which is incorporated herein by reference.~~

~~The New~~On ~~Shares~~November to30, be2025, ~~issued in connection with~~ the ~~Share~~Board ~~Exchange~~of ~~will~~Directors ~~not~~of beQuantumzyme ~~registered~~Corp. ~~under~~ (the ~~Securities~~“Company”) ~~Act,~~approved ~~and~~an ~~will~~amendment beto ~~issued in~~the ~~reliance~~Company’s ~~upon~~Articles ~~the~~of ~~exemption~~Incorporation ~~from~~to ~~registration~~change ~~provided~~the byCompany’s ~~Regulation~~name Sfrom ofQuantumzyme ~~the~~Corp. ~~Securities~~to ~~Act~~Quantum ofGenesis ~~1933,~~AI asCorp. ~~amended~~ (the “~~Securities Act~~Name Change”). ~~Certificates~~On ~~representing~~November ~~these~~30, ~~shares~~2025, ~~will~~the ~~contain~~holder of a ~~legend~~majority ~~stating~~of the ~~restrictions~~voting ~~applicable~~power toof ~~such~~the ~~shares~~Company’s outstanding capital stock approved the Name Change by written consent.

~~Item 3~~The Company has not yet filed the Certificate of Amendment with the Nevada Secretary of State.02 ~~Unregistered~~The ~~Sales~~Certificate of ~~Equity~~Amendment ~~Securities~~will be filed following the completion of the Company’s Schedule 14C information statement process and the expiration of the applicable 20-day waiting period required under federal securities laws, at which time the Name Change may become effective. The Company has filed an Issuer Company-Related Action Notification Form with FINRA to give reflect the Name Change and to apply for a new stock symbol. To this end, we will endeavor to update our shareholders, and the markets generally, upon approval and deemed effectiveness by FINRA.

~~Reference is~~The ~~made~~Name toChange will not affect the ~~disclosure~~rights ~~set~~of ~~forth~~shareholders ~~under~~and ~~Item~~will ~~1.01~~not ofresult ~~this~~in ~~Current~~any ~~Report~~change onto ~~Form~~the ~~8-K~~Company’s authorized capital, ~~which~~issued ~~disclosure~~and isoutstanding ~~incorporated~~shares, ~~herein~~ CUSIP number, or par value. A change to the Company’s ticker symbol will be assigned by ~~reference~~FINRA upon completion of its review of the Company’s corporate action request.

~~The securities described above will be issued in reliance upon exemptions from registration pursuant to Regulation S under the Securities Act of 1933, as amended.~~2

~~Item 9.01. Financial Statements and Exhibits.~~SIGNATURES

Exhibit No.		Description
10.1		Share Exchange Agreement dated October 23, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNATURES

		QUANTUMZYME CORP.

Dated: January 7, 2026		/s/ Naveen Krishnarao Kulkarni
		By: Naveen Krishnarao Kulkarni
		Its: Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~3

Dated: October 23, 2018	Reliant Service Inc.
	By:	/s/ Zhu Ming
		Zhu Ming, CEO

Filing Compare · Quantum Genesis AI Corp.